Connect with us

Louisiana

Buy women's basketball tickets for SE Louisiana vs. New Orleans on February 24

Published

on

Buy women's basketball tickets for SE Louisiana vs. New Orleans on February 24


The SE Louisiana Lions (15-8) meet the New Orleans Privateers (9-14) in a clash of Southland squads at 2:00 PM ET on Saturday.

If you’re looking to go to this matchup in person, head to StubHub or Ticketmaster to buy your tickets!

SE Louisiana vs. New Orleans Game Information

Watch college basketball, other live sports and more on Fubo! Use our link to sign up for a free trial.

Advertisement

Buy Tickets for Other SE Louisiana Games

Rep your team with officially licensed college basketball gear! Head to Fanatics to find jerseys, shirts, and much more.

SE Louisiana Players to Watch

  • Hailey Giaratano: 12.6 PTS, 4.2 REB, 3 AST, 0.9 STL, 0.3 BLK
  • Taylor Bell: 10 PTS, 5.3 REB, 1.7 AST, 2 STL, 0.7 BLK
  • Cheyanne Daniels: 9.3 PTS, 5.5 REB, 0.7 AST, 0.5 STL, 1 BLK
  • Jalencia Pierre: 8.8 PTS, 3.6 REB, 2.7 AST, 1.4 STL, 0 BLK
  • Allasia Washington: 7 PTS, 3.5 REB, 0.2 AST, 0.7 STL, 0.3 BLK

Catch college basketball action all season long on Fubo!

New Orleans Players to Watch

  • Dee Dee Pryor: 13.4 PTS, 4.6 REB, 2 AST, 1.7 STL, 0.1 BLK
  • Alexis Calderon: 8.8 PTS, 3.7 REB, 2.3 AST, 2.7 STL, 0.2 BLK
  • Justice Ross: 7 PTS, 3.9 REB, 2.1 AST, 0.9 STL, 1.3 BLK
  • Jayla Kimbrough: 10 PTS, 4 REB, 0.6 AST, 0.9 STL, 0.2 BLK
  • Nora Francois: 8.5 PTS, 4.7 REB, 0.7 AST, 1 STL, 0.5 BLK

Sportsbook Promo Codes

Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER.

© 2023 Data Skrive. All rights reserved.



Source link

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Louisiana

Louisiana Association of Fairs and Festivals hosts annual convention amid pageant controversy

Published

on

Louisiana Association of Fairs and Festivals hosts annual convention amid pageant controversy


BATON ROUGE – Saturday afternoon was busy for the members of the Louisiana’s Association of Fairs and Festivals, who were prepping for the awards ceremony and pageant Saturday night and Sunday.

The convention was held at Crowne Plaza in Baton Rouge.

“This is really the weekend we come together to celebrate everything fairs and festivals throughout Louisiana,” President of LAFF Katelyn Calhoun said. “Baton Rouge has been our home for a long time and we’re very proud to be here.”

The convention consists of food, breakout sessions, and prepping for the festival season ahead. Festivals which tend to bring in people from across the country. 

Advertisement

According to Explore Louisiana, Louisiana hosts over 400 festivals each year.

“This weekend helps our state because fairs and festivals play a vital role in tourism. Tourism means generating economic dollars to put back into our state,” Calhoun said.

The association hosts over 60 pageant queens during the convention, who compete for the pageant title of LAFF.

In the past year, the evening gown competition section was removed, causing controversy online.

“This year, we have changed a little bit of our pageant format so that we can include our queens a little bit more in our association. We know there were some changes that weren’t popular and that’s okay. We’re going to work through those and work with our membership to better develop some things so that we can make everybody happy at the end of the day,” Calhoun said.

Advertisement

Calhoun declined to comment further on the conflict but believes this decision is for the best.

The annual convention is closed to the public, and is only open for members.

To learn more about the Louisiana Association of Fairs and Festivals, or to become a member, click here.



Source link

Advertisement
Continue Reading

Louisiana

Retracted studies the latest in a decadeslong abortion-science fight – Louisiana Illuminator

Published

on

Retracted studies the latest in a decadeslong abortion-science fight – Louisiana Illuminator


Chris Adkins is worried.

The Georgia pharmaceutical sciences professor who sparked an investigation into scientific studies that led to recent news-making retractions is worried about the “appropriate legal action” researchers have vaguely told media outlets they’re pursuing.

But even more than being sued, Adkins is worried it might be too late to correct the scientific record about a key abortion drug in a high-stakes legal case that is currently before the U.S. Supreme Court. Because before the three studies produced by an anti-abortion think tank were probed and determined to have “fundamental problems with the study design and methodology,” two of them were directly cited by a federal judge in ruling the plaintiffs had legal standing in seeking to strip mifepristone of federal approval. And now the anti-abortion researchers have claimed the retractions are a result of pro-abortion politics while downplaying their own significant roles in the consequential case.

“The main concern is that now, instead of focusing on the science, it’s going to be contorted and twisted as a political maneuver,” Adkins told States Newsroom in a phone interview. “I don’t mind my name being thrown out there. … But my initial concern was driven purely by the issues I had with the very science and the communication of that science.”

Advertisement

On Feb. 5, academic publisher Sage Journals announced it was retracting three of Charlotte Lozier Institute’s studies about abortion published in the journal “Health Services Research and Managerial Epidemiology” between 2019 and 2022. Among them was research that questioned the safety of mifepristone, a commonly used abortion and miscarriage medication. The reasons Sage cited included undeclared conflicts of interest involving several of the papers’ authors, who had an affiliation with “pro-life advocacy organizations that explicitly support judicial action to restrict access to mifepristone.” Some of the authors are plaintiffs or expert witnesses in the lawsuit.

While Adkins and California-based epidemiologist and reproductive health expert Ushma Upadhyay work to publish a scientific examination of the now-retracted research and the Supreme Court hearing looms large, experts say the nation’s highest court is unlikely to give serious consideration to the exposed ambiguities in a decision that could have repercussions beyond reproductive health care.

From the beginning, reproductive health, pharmaceutical, and legal experts have warned that an outcome in favor of the anti-abortion medical groups and doctors who sued the U.S. Food and Drug Administration in November 2022 could limit access to mifepristone with a decadeslong record of safety and efficacy — and upend federal drug policy in the process.

“The failure to routinely engage in rigorous vetting processes undermines the integrity of our judicial system and raises concerns about our federal courts’ ability to appraise scientific and medical evidence presented in their courtrooms,” Adkins told States Newsroom in a follow-up written statement.

The Charlotte Lozier Institute, the nonprofit research arm of the anti-abortion powerhouse Susan B. Anthony Pro-Life America, employs scholars who for decades have produced research used to defend anti-abortion laws. That work included the 2021 article that U.S. District Judge Matthew Kacsmaryk cited as evidence that plaintiffs had standing to sue and was published exactly one year before they filed suit in Amarillo, Texas, one of the most conservative federal district courts in the country.

Advertisement

A couple months before filing the lawsuit, they registered a nonprofit called the Alliance for Hippocratic Medicine, which became the lead plaintiff in the case. The principal officer of the Alliance, according to the Internal Revenue Service, is Dr. Donna Harrison, an OB-GYN and the recently retired CEO of the American Association of Pro-life Obstetricians & Gynecologists (AAPLOG), which is also a plaintiff. Additionally, Harrison is one of the authors of three retracted studies.

The Charlotte Lozier Institute scholars have vigorously defended their research, while downplaying their significant roles in the FDA lawsuit.

“What happened to us has little or nothing to do with real science; it has everything to do with political assassination of good science,” said James Studnicki, Charlotte Lozier vice president and director of data analytics, in a video uploaded to a website the group recently launched to challenge the retractions. Studnicki was the lead author of the three retracted studies and an expert witness for the three red states that tried to intervene in the lawsuit alongside plaintiffs. The Supreme Court on Tuesday denied Missouri, Kansas, and Idaho’s motion to intervene.

Studnicki and Charlotte Lozier Institute senior research associate Tessa Longbons told States Newsroom in a written statement that this is a “baseless ideological attack” and that Sage has never “identified a single substantive objection to the studies.”

Meanwhile they maintain that the Supreme Court can overturn FDA policy on mifepristone on the basis of their work.

Advertisement

“The Supreme Court can rely on our findings,” Studnicki recently told Science magazine.

Experts also have said they don’t believe the retractions will affect the Supreme Court’s ultimate decision.

“There’s been a lot of people who’ve been criticizing the science used [by plaintiffs] as junk science. And I think this is just further proof that it’s junk science,” Drexel University law professor and reproductive rights advocate David Cohen told States Newsroom. “That being said, I think that the judges will find a way to support the view that they feel like they want to reason towards, and two studies disappearing is not going to change that.”

GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Advertisement

A case that hinges on science

It took about four years before the U.S. Food and Drug Administration approved mifepristone in 2000 as part of a two-drug abortion regimen for first-trimester abortions: The mifepristone is taken first to block the hormone progesterone, followed by the ulcer medication misoprostol which causes the uterus to contract. After nearly two decades of data showing the regimen has a high rate of efficacy and a low rate of serious adverse events, the federal agency lowered the dosage and loosened restrictions.

But the Alliance for Hippocratic Medicine asked federal courts to order the FDA to revoke its approval of mifepristone, or at minimum roll back more recent changes authorizing its availability via telemedicine and at pharmacies.

Advertisement

The case began with an initial victory for plaintiffs in district court, when Kacsmaryk ruled to suspend mifepristone’s FDA approval. The U.S. 5th Circuit Court of Appeals overturned the full drug suspension, but upheld the lower court decision to reinstate outdated restrictions. The U.S. Supreme Court will hear the case March 26.

Going back to the pre-2016 regimen in practice would mean shortening the gestational window the drug can be used, from 10 to seven weeks. It would require three in-clinic appointments and prohibit telemedicine and pharmacy dispensation. The old regimen also calls for a higher dose of mifepristone, which goes against current recommended guidelines.

Reproductive health experts say these FDA rollbacks would limit access to even more people, now that abortion is banned or heavily restricted in nearly half the country.

As States Newsroom has previously reported, the plaintiffs’ submitted evidence that mifepristone is a high-risk drug includes a small number of studies produced by a small anti-abortion medical community, along with anecdotes by the doctor plaintiffs. Defendants, in contrast, have submitted hundreds of studies.

Adding to this pool of research is a brand-new study in “Nature Medicine,” co-authored by Upadhyay, an associate professor at the University of California San Francisco, which found a low rate of serious abortion-related adverse events for patients who took medication abortion via telemedicine.

Advertisement

But none of that has stopped the plaintiffs’ legal team, the powerful Christian right Alliance Defending Freedom (a funding source for the Charlotte Lozier Institute and co-plaintiff AAPLOG), from asserting publicly and in court that mifepristone is dangerous. One of the plaintiffs’ key claims that stems directly from the 2021 paper is that emergency room visits within 30 days following a medication abortion increased 500% from 2002 to 2015.

In this study, researchers looked at Medicaid data in 17 states between 1999 and 2015. They tracked patients who had had a procedural or a medication abortion and counted each time they went to an emergency department in the 30 days following those abortions.

Upadhyay said among her main concerns with the 2021 paper is that the researchers inflated their findings, and appear to conflate all emergency department visits with adverse events. She said they lumped in people going in for just observation to make sure bleeding is normal with people who needed significant intervention.

“A national study found more than 50% of ER visits after abortion involve observational care only — indicating that an adverse event did not occur. But even a visit that involves an aspiration procedure to treat retained products of conception after an abortion is not considered a true complication. It is expected that about 3-5% of people who have a medication abortion will require an additional procedure to complete the abortion,” Upadhyay told States Newsroom in a follow-up written statement. “Studnicki et al. sensationalize and obfuscate the growth in ER visits after medication abortion. The authors downplay that their data demonstrates the vast majority of postabortion ER visits were not abortion-related (based on ICD-9 codes) and abortion-related ER visits were uncommon.”

The Charlotte Lozier authors defended their study design in a rebuttal to Sage, and argued that abortion complications are typically underreported. “The ER visit can be for any number of complications and is, therefore, a broad proxy indicator for abortion-related morbidity,” they wrote.

Advertisement

Adkins said also problematic was how the authors communicated their findings, ultimately concluding “mifepristone abortion is consistently and progressively associated with increased morbidity.”

“You know, scientists, we get so enrapt, and enveloped in our work, that we forget that the very language we use to describe our work is sometimes foreign to others,” Adkins said. “We have a duty to communicate our findings in a way that is accurate, honest, and can be interpreted by all. That’s difficult. And I think that the Studnicki articles, I think there are portions of it that take advantage of that to generate misinterpretation, and that is then turned around and used to fuel these lawsuits.”

Pharmaceutical professor Chris Adkins and epidemiologist and reproductive health expert Ushma Upadhyay are working to publish a scientific examination of the now-retracted research used to challenge federal approval of the abortion medication mifepristone. (Courtesy Chris Adkins)

Based on Adkins’ concerns, Sage re-examined the peer review process and found that one of the initial peer reviewers was an associate scholar with the Charlotte Lozier Institute. The publisher then enlisted a statistician and two reproductive health experts to newly peer review the Charlotte Lozier articles.

“Following Committee on Publication Ethics (COPE) guidelines, we made this decision with the journal’s editor because of undeclared conflicts of interest and after expert reviewers found that the studies demonstrate a lack of scientific rigor that invalidates or renders unreliable the authors’ conclusions,” reads Sage’s public note on the retractions.

As part of their rebuttal to the retractions, the Charlotte Lozier team has said the process is double-blind, so the researchers couldn’t have known who the peer reviewer was.

Advertisement

Studnicki was on the journal’s editorial board until last fall, but the journal’s editor-in-chief dismissed him after the journal and Sage decided to retract the papers.

“The editorial board members at HSRME (Health Services Research and Managerial Epidemiology) act as ambassadors of the journal and in turn, of the Publisher to help uphold the highest standards of quality and integrity in scholarly publishing,” Dr. Gregory M. Garrison wrote Studnicki in an email dated Nov. 14, 2023, and shared by Charlotte Lozier. “In light of the decision to retract three research articles where you are an author, I believe that your term as editorial board member must now come to an end.”

The Charlotte Lozier team has insisted the retraction of their research is based on politics rather than science. But research experts say retraction is a high bar to clear, and journals are reluctant to retract in fear of lawsuits.

Ivan Oransky, who teaches medical journalism at New York University and co-founded the blog Retraction Watch, told States Newsroom that retractions are slightly on the rise because of the rise of fraudulent paper mills. But he said a lot of mediocre science goes under the radar unless someone brings it to the attention of the journal.

“There are an awful lot of other papers that should also probably be retracted,” Oransky said. “If you were to hold all papers to the same actual standards, far more would be retracted.”

Advertisement

Conflicts of interest

In their Assault on Science website, the Charlotte Lozier team refers to Adkins, an associate professor and director of assessment at South University School of Pharmacy* in Savannah, Georgia, as someone who “supports abortion.”

As Adkins told States Newsroom last year, the fall of Roe v. Wade on his birthday coupled with a baby on the way made him more concerned about reproductive rights. But the once conservative Texan said he had never formally advocated for abortion access. In his spare time, he reads FDA news, which is how he eventually fell down a rabbit hole trying to understand how this research was produced and whether it was ideologically biased.

After reaching out to the journal and publisher, Adkins started consulting with reproductive health experts and earlier this year was invited to sign onto an amicus brief filed in the FDA case, of over 300 reproductive health researchers, defending the science behind mifepristone. Adkins maintains that his major issue in this case is the lack of quality in the science used by plaintiffs.

“My decision to notify Sage was prompted following a federal district judge’s citation of the 2021 article, wherein language was used that was inconsistent and inaccurate relative to the cited work,” Adkins told States Newsroom. “I believe it is both a professional obligation and a right to bring attention to legitimate concerns within scientific and medical literature; this practice is not ‘activism’ — instead, it is the self-correcting feature of scientific progress.”

The Charlotte Lozier researchers have objected to a larger accusation of an ideological conflict of interest, arguing that many authors of reproductive health articles that have been published in Sage journals also advocate for abortion access.

Advertisement

But Sage defended its retraction decision.

“Investigations are often initiated from readers’ complaints, as was the case in this matter regarding an issue of the presentation of data, and in the course of the investigation the undisclosed conflicts of interest became glaring,” Sage attorney Ronni Sander wrote to Charlotte Lozier attorney David A. Shaneyfelt in a letter dated Nov. 21, 2023, published on the Assault on Science website. “However, the substantive findings by the reviewers were most significant in the determination that retraction of the articles was necessary under COPE … guidance.”

Upadhyay says she agrees that most authors, including herself, are biased toward certain policy outcomes but are called as scientists to follow the science rather than their biases.

“As a health-care researcher, I have an interest in expanding access to abortion, because I believe abortion is healthcare,” Upadhyay said. “So everyone is going to come to a question with their own set of beliefs. … For me, the conflict of interest is more about the fact that Studnicki was on the editorial board and that the peer reviewers [it was only one peer reviewer, according to Sage] were from the same institution. And most importantly, that they can approach the research question with scientific integrity … that they acknowledge their bias but they still stick to scientific rigor. And that they did not do.”

And while the authors did declare that they were affiliated with the Charlotte Lozier Institute, they did not disclose the extent several of them are directly involved in the mifepristone lawsuit. Or that they received funding from the law firm suing the FDA.

Advertisement

The Alliance Defending Freedom in 2021 donated more than $27,000 to the Charlotte Lozier Institute and $25,000 to AAPLOG. Among the Charlotte Lozier’s “core activities” reported in its 2022 tax filing include producing white papers and studies cited in the case that overturned Roe v. Wade and in post-Roe cases since: “After the Court’s ruling in June 2022, CLI provided expert commentary and information in media and policy forums across the nation, contributing to the restoration of protective laws in place before the 1973 Supreme Court rulings in Roe and Doe.”

The filing also specifically references the research published in their 2021 paper: “Leveraging millions of data points from Medicaid claims data, Charlotte Lozier Institute scholars identified a dramatic spike in abortion pill related emergency room visits.”

Influence of the retracted science

Upadhyay says that even if the retractions ultimately have no legal impact on the case, they matter.

“There’s a court of public opinion,” Upadhyay told States Newsroom. “If the public is made aware that this article was retracted and yet this article is part of the reason the plaintiffs have standing, I think that it will become even more clear that the ultimate decision the Supreme Court makes, if they do rule against access to mifepristone, it will become more clear that that decision was not based in science. So I still think it’s important that it was retracted before the deliberation.”

Attorneys for the Alliance Defending Freedom have said the retractions should have no bearing on the case.

Advertisement

“ADF has never relied on these studies for the issues that are currently before the Supreme Court,” ADF Senior Counsel Erik Baptist told States Newsroom in a written statement. “So this will not have any impact on the court’s consideration.”

However, ADF cited the research frequently to make its claims that mifepristone is a risky drug. “The number of chemical abortion-related emergency room visits increased by over five hundred percent between 2002 and 2015,” reads an ADF primer on the case. “Women can face severe bleeding and life-threatening infections — requiring emergency medical treatment, surgeries, blood transfusions, and hysterectomies — as well as the inability to have future successful pregnancies.”

Kacsmaryk in turn cited the 2021 paper to argue plaintiffs’ standing “because they allege adverse events from chemical drugs can overwhelm the medical system.” He cited the 2022 paper using the same dataset in affirming plaintiffs’ claims that loosening FDA regulations has led to “‘many intense side effects’ and ‘significant complications requiring medical attention.’” The 2022 paper was cited just one day after the reactions in a brief filed by the intervening states.

The researchers themselves claim they have been influential.

“Sage is targeting us because we have been successful for a long period of time,” Studnicki says in his video uploaded to the Charlotte Lozier’s Assault on Science website. “These findings have been used in a legal action in many of the states. We have become visible. People are quoting us, and for that reason we are dangerous. And for that reason, they want to cancel our work.”

Advertisement



Source link

Continue Reading

Louisiana

SE Louisiana Lions vs. New Orleans Privateers: How to watch online, live stream info, start time, TV channel

Published

on

SE Louisiana Lions vs. New Orleans Privateers: How to watch online, live stream info, start time, TV channel


Who’s Playing

New Orleans Privateers @ SE Louisiana Lions

Current Records: New Orleans 8-19, SE Louisiana 13-14

How To Watch

What to Know

We’ve got another exciting Southland matchup on schedule as the SE Louisiana Lions and the New Orleans Privateers are set to tip at 4:30 p.m. ET on February 24th at Pride Roofing University Center. Given that the pair suffered a loss in their last game, they both have a little extra motivation heading into this match.

SE Louisiana unfortunately witnessed the end of their six-game winning streak on Monday. They fell 77-72 to the Cardinals. SE Louisiana didn’t live up to their potential and found themselves falling short of the advantage oddsmakers thought they had coming into the game.

Advertisement

Meanwhile, New Orleans’ recent rough patch got a bit rougher on Monday after their fourth straight defeat. They took a 89-77 hit to the loss column at the hands of the Colonels. New Orleans found out winning isn’t easy when you make eight fewer threes than your opponent.

The Lions’ defeat ended a four-game streak of wins at home and dropped them to 13-14. As for the Privateers, they have not been sharp recently as the team’s lost ten of their last 11 matches, which put a noticeable dent in their 8-19 record this season.

Looking forward to Saturday, SE Louisiana is the favorite in this one, as the experts expect to see them win by 10.5 points. This contest will be their sixth straight as the favorites (so far over this stretch they are 2-3 against the spread).

SE Louisiana was able to grind out a solid victory over the Privateers in their previous meeting back in January, winning 73-68. Does SE Louisiana have another victory up their sleeve, or will the Privateers turn the tables on them? We’ll have the answer soon enough.

Odds

SE Louisiana is a big 10.5-point favorite against New Orleans, according to the latest college basketball odds.

Advertisement

The oddsmakers had a good feel for the line for this one, as the game opened with the Lions as a 11-point favorite.

The over/under is 148.5 points.

See college basketball picks for every single game, including this one, from SportsLine’s advanced computer model. Get picks now.

Series History

SE Louisiana has won 6 out of their last 10 games against New Orleans.

  • Jan 06, 2024 – SE Louisiana 73 vs. New Orleans 68
  • Mar 06, 2023 – New Orleans 82 vs. SE Louisiana 78
  • Jan 28, 2023 – SE Louisiana 80 vs. New Orleans 64
  • Jan 26, 2023 – SE Louisiana 92 vs. New Orleans 87
  • Mar 11, 2022 – SE Louisiana 74 vs. New Orleans 65
  • Feb 24, 2022 – SE Louisiana 84 vs. New Orleans 79
  • Jan 20, 2022 – New Orleans 78 vs. SE Louisiana 72
  • Mar 10, 2021 – New Orleans 80 vs. SE Louisiana 63
  • Mar 06, 2021 – New Orleans 81 vs. SE Louisiana 76
  • Jan 30, 2021 – SE Louisiana 79 vs. New Orleans 73





Source link

Advertisement
Continue Reading

Trending